Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

The deal values Mitsubishi Tanabe Pharma at about ¥510 billion ($3.3 billion), according to a statement on Friday. The transaction is expected to be completed in the third quarter, pending ...

Mitsubishi Tanabe Pharma, to the US investment firm Bain Capital for about $3.3 billion. Mitsubishi Chemical says it will invest proceeds from the sale in green specialty chemicals, which it has ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

In its third-quarter results update, the company confirmed that it is halting further development of fasinumab, an NGF drug partnered with Teva and Mitsubishi Tanabe Pharma that was in phase 3 ...

The stakes are clear. Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 billion by streamlining the resource- and time ...

Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical’s strategy to streamline its operations and concentrate on core sectors such as vehicle electrification, ...

Win two tickets to Strictly Come Dancing's Launch Show 2025! Greg's giving you the chance to be at the launch show for Strictly Come Dancing. Win tickets to a behind the scenes tour of the Match ...

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The U.S. Food and Drug Administration ...